The prognostic significance of CD44V6, CDH11, and β -Catenin expression in patients with osteosarcoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Deng, Zhouming ^a   Niu, Guangfeng ^b   Cai, Lin ^a   Wei, Renxiong ^a   Zhao, Xiaolei ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD44V6 ANTIGEN; CDH11 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CADHERIN; CTNNB1 PROTEIN, HUMAN; HERMES ANTIGEN; OSTEOBLAST CADHERIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OSTEOCHONDROMA; OSTEOSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL TIME; BONE TUMOR; CHEMISTRY; CHINA; MIDDLE AGED; MORTALITY; PREVALENCE; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; YOUNG ADULT; BONE NEOPLASMS; EPIDEMIOLOGY;

ADOLESCENT; ADULT; ANTIGENS, CD44; BETA CATENIN; BONE NEOPLASMS; CADHERINS; CHILD; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84881538378     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/496193     Document Type: Article

References (58)

1. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology-Bone Cancer 2012. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp
2. The ESMO/European Sarcoma Network Working Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 23 supplement 7 vii100 vii109
3. Kong C., Hansen M. F., Biomarkers in osteosarcoma. Expert Opinion on Medical Diagnostics 2009 3 1 13 23 2-s2.0-77953404424 10.1517/17530050802608496
4. Wagner E. R., Luther G., Zhu G., Luo Q., Shi Q., Kim S. H., Gao J.-L., Huang E., Gao Y., Yang K., Wang L., Teven C., Luo X., Liu X., Li M., Hu N., Su Y., Bi Y., He B.-C., Tang N., Luo J., Chen L., Zuo G., Rames R., Haydon R. C., He T.-C., Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma 2011 2011 12 2-s2.0-79955082926 10.1155/2011/325238 325238
5. Osborne T. S., Khanna C., A review of the association between osteosarcoma metastasis and protein translation. Journal of Comparative Pathology 2012 146 2-3 132 142 2-s2.0-84858623789 10.1016/j.jcpa.2011.12.007
6. Hattinger C. M., Pasello M., Ferrari S., Picci P., Serra M., Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs 2010 15 4 615 634 2-s2.0-78649460883 10.1517/14728214.2010.505603
7. Nakajima G., Patino-Garcia A., Bruheim S., Xi Y., San Julian M., Lecanda F., Sierrasesumaga L., Müller C., Fodstad O., Ju J., CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics and Proteomics 2008 5 1 37 42 2-s2.0-40549119857 (Pubitemid 351363373)
8. Kuryu M., Ozaki T., Nishida K., Shibahara M., Kawai A., Inoue H., Expression of CD44 variants in osteosarcoma. Journal of Cancer Research and Clinical Oncology 1999 125 11 646 652 2-s2.0-0032733533 10.1007/s004320050329 (Pubitemid 29502347)
9. Iwaya K., Ogawa H., Kuroda M., Izumi M., Ishida T., Mukai K., Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clinical and Experimental Metastasis 2003 20 6 525 529 2-s2.0-0142029993 10.1023/A:1025821229013 (Pubitemid 37297180)
10. Brown R. L., Reinke L. M., Damerow M. S., Perez D., Chodosh L. A., Yang J., Cheng C., CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. Journal of Clinical Investigation 2011 121 3 1064 1074 2-s2.0-79952227361 10.1172/JCI44540
11. Jung T., Gross W., Zöller M., CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. Journal of Biological Chemistry 2011 286 18 15862 15874 2-s2.0-79955541291 10.1074/jbc.M110.208421
12. Zhang X. G., Lu X. F., Jiao X. M., Chen B., Wu J. X., PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Experimental and Therapeutic Medicine 2012 4 6 1005 1009
13. Zhou Z. J., Dai Z., Zhou S. L., Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. International Journal of Cancer 2013 132 5 1080 1089 10.1002/ijc.27742
14. Kaur H., Phillips-Mason P. J., Burden-Gulley S. M., Kerstetter-Fogle A. E., Basilion J. P., Sloan A. E., Brady-Kalnay S. M., Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. Molecular Cancer Research 2012 10 3 293 304 2-s2.0-84858613653 10.1158/1541-7786.MCR-11-0457
15. Yagi T., Takeichi M., Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes and Development 2000 14 10 1169 1180 2-s2.0-0034657319 (Pubitemid 30327498)
16. Berx G., van Roy F., Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspectives in Biology 2009 1 6 a003129 2-s2.0-77953879928 10.1101/cshperspect.a003129
17. Brieger J., Duesterhoeft A., Brochhausen C., Gosepath J., Kirkpatrick C. J., Mann W. J., Recurrence of pleomorphic adenoma of the parotid gland-predictive value of cadherin-11 and fascin. APMIS 2008 116 12 1050 1057 2-s2.0-58149194947 10.1111/j.1600-0463.2008.01088.x
18. Thomas D. M., Wnts, bone and cancer. Journal of Pathology 2010 220 1 1 4 2-s2.0-73649088338 10.1002/path.2635
19. Haydon R. C., Deyrup A., Ishikawa A., Heck R., Jiang W., Zhou L., Feng T., King D., Cheng H., Breyer B., Peabody T., Simon M. A., Montag A. G., He T.-C., Cytoplasmic and/or nuclear accumulation of the β -catenin protein is a frequent event in human osteosarcoma. International Journal of Cancer 2002 102 4 338 342 2-s2.0-0036888309 10.1002/ijc.10719 (Pubitemid 35265873)
20. Enneking W. F., Spanier S. S., Goodman M., A system for the surgical staging of musculoskeletal sarcoma. Clinical Orthopaedics and Related Research 1980 153 106 120 2-s2.0-0019202519 (Pubitemid 11217753)
21. Gun B. D., Bahadir B., Bektas S., Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagnostic Pathology 2012 7 article 80 10.1186/1746-1596-7-80
22. Cai Y., Mohseny A. B., Karperien M., Hogendoorn P. C. W., Zhou G., Cleton-Jansen A.-M., Inactive Wnt/ β -catenin pathway in conventional high-grade osteosarcoma. Journal of Pathology 2010 220 1 24 33 2-s2.0-73649132981 10.1002/path.2628
23. Stephens P. J., Greenman C. D., Fu B., Yang F., Bignell G. R., Mudie L. J., Pleasance E. D., Lau K. W., Beare D., Stebbings L. A., McLaren S., Lin M.-L., McBride D. J., Varela I., Nik-Zainal S., Leroy C., Jia M., Menzies A., Butler A. P., Teague J. W., Quail M. A., Burton J., Swerdlow H., Carter N. P., Morsberger L. A., Iacobuzio-Donahue C., Follows G. A., Green A. R., Flanagan A. M., Stratton M. R., Futreal P. A., Campbell P. J., Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011 144 1 27 40 2-s2.0-78650959663 10.1016/j.cell.2010.11.055
24. Rausch T., Jones D. T. W., Zapatka M., Stütz A. M., Zichner T., Weischenfeldt J., Jäger N., Remke M., Shih D., Northcott P. A., Pfaff E., Tica J., Wang Q., Massimi L., Witt H., Bender S., Pleier S., Cin H., Hawkins C., Beck C., Von Deimling A., Hans V., Brors B., Eils R., Scheurlen W., Blake J., Benes V., Kulozik A. E., Witt O., Martin D., Zhang C., Porat R., Merino D. M., Wasserman J., Jabado N., Fontebasso A., Bullinger L., Rücker F. G., Döhner K., Döhner H., Koster J., Molenaar J. J., Versteeg R., Kool M., Tabori U., Malkin D., Korshunov A., Taylor M. D., Lichter P., Pfister S. M., Korbel J. O., Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012 148 1-2 59 71 2-s2.0-84856091910 10.1016/j.cell.2011.12.013
25. Saadatmand S., de Kruijf E. M., Sajet A., Expression of cell adhesion molecules and prognosis in breast cancer. The British Journal of Surgery 2013 100 2 252 260 10.1002/bjs.8980
26. Park J. S., Kim K. M., Kim M. H., Chang H. J., Baek M. K., Kim S. M., Jung Y. D., Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 expression. Anticancer Research 2009 29 1 355 362 2-s2.0-61449205308
27. Zhou G., Chiu D., Qin D., Detection and clinical significance of CD44v6 and integrin-beta1 in pancreatic cancer patients using a triplex real-time RT-PCR assay. Applied Biochemistry and Biotechnology 2012 167 8 2257 2268 10.1007/s12010-012-9752-2
28. Garouniatis A., Zizi-Sermpetzoglou A., Rizos S., Kostakis A., Nikiteas N., Papavassiliou A. G., FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. International Journal of Colorectal Disease 2013 28 1 9 18 10.1007/s00384-012-1520-9
29. Shi J., Zhou Z., Di W., Li N., Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 2013 13 article 182
30. Omran O. M., Ata H. S., CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastructural Pathology 2012 36 3 145 152
31. Affy A. M., Tate S., Durbin-Johnson B., Rocke D. M., Konia T., Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. International Journal of Biological Markers 2011 26 1 50 57 2-s2.0-79953656478 10.5301/JBM.2011.6291
32. Jijiwa M., Demir H., Gupta S., Leung C., Joshi K., Orozco N., Huang T., Yildiz V. O., Shibahara I., de Jesus J. A., Yong W. H., Mischel P. S., Fernandez S., Kornblum H. I., Nakano I., CD44V6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011 6 9 2-s2.0-80052445685 10.1371/journal.pone.0024217 e24217
33. Fan C. W., Wen L., Qiang Z. D., Prognostic significance of relevant markers of cancer stem cells in colorectal cancer-a meta analysis. Hepatogastroenterology 2012 59 117 1421 1427 10.5754/hge10727
34. Marhaba R., Bourouba M., Zöller M., CD44v6 promotes proliferation by persisting activation of MAP kinases. Cellular Signalling 2005 17 8 961 973 2-s2.0-19344377475 10.1016/j.cellsig.2004.11.017 (Pubitemid 40719117)
35. Jijiwa M., Demir H., Gupta S., Leung C., Joshi K., Orozco N., Huang T., Yildiz V. O., Shibahara I., de Jesus J. A., Yong W. H., Mischel P. S., Fernandez S., Kornblum H. I., Nakano I., CD44V6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011 6 9 2-s2.0-80052445685 10.1371/journal.pone.0024217 e24217
36. Nakajima K., Taniguchi K., Mutoh K.-I., Expression of CD44v6 as matrix-associated ectodomain in the bone development. Journal of Veterinary Medical Science 2010 72 8 1017 1022 2-s2.0-77957662148 10.1292/jvms.10-0002
37. Orian-Rousseau V., CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010 46 7 1271 1277 2-s2.0-77950561915 10.1016/j.ejca.2010.02.024
38. Yang S., Wang H.-P., Wang X.-Y., Guo L.-J., Tang X.-F., Gao Q.-H., Xuan M., Loo W. T. Y., Chow L. W. C., Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Expert Opinion on Investigational Drugs 2010 19 supplement 1 S101 S108 2-s2.0-77950670256 10.1517/ 13543781003718866
39. Spafford M. F., Koeppe J., Pan Z., Archer P. G., Meyers A. D., Franklin W. A., Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Archives of Otolaryngology-Head and Neck Surgery 1996 122 6 627 632 2-s2.0-0029992488 (Pubitemid 26178794)
40. Mack B., Gires O., CD44s and CD44v6 expression in head and neck epithelia. PLoS One 2008 3 10 2-s2.0-54449085703 10.1371/journal.pone.0003360 e3360
41. Heyse T. J., Malcherczyk D., Moll R., Timmesfeld N., Wapelhorst J., Fuchs-Winkelmann S., Paletta J. R. J., Schofer M. D., CD44: survival and metastasis in chondrosarcoma. Osteoarthritis and Cartilage 2010 18 6 849 856 2-s2.0-77952877280 10.1016/j.joca.2010.02.007
42. Kim H.-S., Park Y.-B., Oh J. H., Jeong J., Kim C. J., Lee S. H., Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clinical Orthopaedics and Related Research 2002 396 184 190 2-s2.0-0036186496 (Pubitemid 34207970)
43. Gun B. D., Bahadir B., Bektas S., Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagnostic Pathology 2012 7 article 80 10.1186/1746-1596-7-80
44. Carmona F. J., Villanueva A., Vidal A., Epigenetic disruption of cadherin-11 in human cancer metastasis. The Journal of Pathology 2012 228 2 230 240 10.1002/path.4011
45. Li L., Ying J., Li H., Zhang Y., Shu X., Fan Y., Tan J., Cao Y., Tsao S. W., Srivastava G., Chan A. T. C., Tao Q., The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/ β -catenin signaling and silenced in common carcinomas. Oncogene 2012 31 34 3901 3912 2-s2.0-82455186748 10.1038/onc.2011.541
46. Marchong M. N., Yurkowski C., Ma C., Spencer C., Pajovic S., Gallie B. L., Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death. PLoS Genetics 2010 6 4 e1000923 2-s2.0-77952396433 10.1371/journal.pgen.1000923
47. Kashima T., Kawaguchi J., Takeshita S., Kuroda M., Takanashi M., Horiuchi H., Imamura T., Ishikawa Y., Ishida T., Mori S., Machinami R., Kudo A., Anomalous cadherin expression in osteosarcoma: possible relationships to metastasis and morphogenesis. American Journal of Pathology 1999 155 5 1549 1555 2-s2.0-0032732675
48. Kashima T., Nakamura K., Kawaguchi J., Takanashi M., Ishida T., Aburatani H., Kudo A., Fukayama M., Grigoriadis A. E., Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. International Journal of Cancer 2003 104 2 147 154 2-s2.0-0037457309 10.1002/ijc.10931 (Pubitemid 36249788)
49. Grivennikov S. I., Greten F. R., Karin M., Immunity, Inflammation, and Cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
50. Warde N., Inflammation: cadherin 11: a key mediator of fibroblast inflammation. Nature Reviews Rheumatology 2011 7 7 374 2-s2.0-79959921187 10.1038/nrrheum.2011.85
51. Hill T. P., Später D., Taketo M. M., Birchmeier W., Hartmann C., Canonical Wnt/ β -catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell 2005 8 5 727 738 2-s2.0-17844363974 10.1016/j.devcel.2005.02.013 (Pubitemid 40585295)
52. Kansara M., Tsang M., Kodjabachian L., Sims N. A., Trivett M. K., Ehrich M., Dobrovic A., Slavin J., Choong P. F. M., Simmons P. J., Dawid I. B., Thomas D. M., Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. Journal of Clinical Investigation 2009 119 4 837 851 2-s2.0-65249167488 10.1172/JCI37175
53. Bongiovanni L., Mazzocchetti F., Malatesta D., Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β -catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Veterinary Research 2012 8 article 78
54. Zhang F., Chen A., Chen J., Yu T., Guo F., Influence of β -catenin small interfering RNA on human osteosarcoma cells. Journal of Huazhong University of Science and Technology-Medical Science 2011 31 3 353 358 2-s2.0-80455167875 10.1007/s11596-011-0380-9
55. Guimarães A. P. G., Rocha R. M., da Cunha I. W., Guimarães G. C., Carvalho A. L., De Camargo B., Lopes A., Squire J. A., Soares F. A., Prognostic impact of adenomatous polyposis coli gene expression in osteosarcoma of the extremities. European Journal of Cancer 2010 46 18 3307 3315 2-s2.0-78649634428 10.1016/j.ejca.2010.06.004
56. Piskun C. M., Muthuswamy A., Huelsmeyer M. K., Thompson V., Stein T. J., Wnt/ β -catenin expression does not correlate with serum alkaline phosphatase concentration in canine osteosarcoma patients. PLoS One 2011 6 10 2-s2.0-80053993085 10.1371/journal.pone.0026106 e26106
57. Deng J., Miller S. A., Wang H.-Y., Xia W., Wen Y., Zhou B. P., Li Y., Lin S.-Y., Hung M.-C., β -catenin interacts with and inhibits NF- B in human colon and breast cancer. Cancer Cell 2002 2 4 323 334 2-s2.0-0036781671 10.1016/S1535-6108(02)00154-X (Pubitemid 41043966)
58. Masaki T., Goto A., Sugiyama M., Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 2001 92 10 2539 2546 (Pubitemid 33049436)